GenSight Biologics to Present at June 2024 Conferences and Meetings

GenSight Biologics, a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced its participation in several significant medical and stakeholder meetings throughout the remainder of 2024. The company, listed on Euronext under the ticker symbol SIGHT, is particularly focused on the gene therapy LUMEVOQ®, designed to treat Leber Hereditary Optic Neuropathy (LHON).

On June 4, three important papers on LUMEVOQ® will be presented at the 16th Meeting of the European Neuro-Ophthalmology Society (EUNOS) in Rotterdam, the Netherlands, which takes place from June 3-6, 2024. The first presentation, titled "Efficacy and Safety of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting," will be showcased as a poster by Dr. Catherine Vignal from the Quinze-Vingts National Eye Hospital in Paris, France. This presentation is scheduled for Poster Session 1 on June 4, from 1:00 - 2:00 pm CEST, at Poster Area – Poster P-099.

Another significant presentation is "Meta-Analysis of Treatment Outcomes for Patients With m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy," which will also be presented in a poster format by Dr. Nancy J. Newman from Emory University School of Medicine in Atlanta, USA. This presentation will occur during the same session and location, specifically at Poster Area – Poster P-101.

The third paper, "Ocular Post-Mortem Analyses with Histopathological and Molecular Assessments in LHON Following AAV2 Gene Therapy," will be presented by Valerio Carelli from the University of Bologna and IRCCS Istituto delle Scienze Neurologiche, Ospedale Bellaria, Italy. This presentation will be featured twice on June 4: first during Poster Session 1 from 1:00 - 2:00 pm CEST at Poster Area – Poster P-093, and later during the Rapid Fire Poster Session from 3:12 – 3:18 pm CEST at Willem Burger Zaal – Presentation S03-13.

In addition to the EUNOS meeting, papers on LUMEVOQ® will also be presented at two other major conferences later in the year: the 2024 Annual Meeting of the American Academy of Ophthalmology (AAO) and the 27th Annual Congress of the European Association for Vision and Eye Research (EVER). The specific dates and times for these presentations will be announced in due course.

On June 5, Magali Taiel, Chief Medical Officer of GenSight Biologics, is slated to speak at the 2nd Multi-Stakeholders Meeting on Clinical Trials for Inherited Retinal Diseases, organized by the ERN-EYE, a European Reference Network dedicated to rare eye diseases. Additionally, Dr. Taiel will participate as a speaker at the 2024 Mitochondrial Disease Conference in October, an event organized by Mitocon, a patient advocacy group, and endorsed by the EURO-NMD, a European Reference Network for rare neuromuscular diseases.

GenSight Biologics, headquartered in Paris, specializes in leveraging advanced technologies such as the Mitochondrial Targeting Sequence (MTS) and optogenetics to preserve or restore vision in patients with blinding retinal diseases. Their lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational gene therapy developed to treat LHON, a rare mitochondrial disorder causing irreversible blindness in primarily young individuals. The therapy is administered through a single intravitreal injection to each eye, aiming to provide a sustainable functional visual recovery.